BioAdaptives, Inc. (BDPT) director receives Series D preferred stock grant
Rhea-AI Filing Summary
BioAdaptives, Inc. director Mark P. Frissora reported an award of Series D Convertible Preferred Stock as board compensation. He received 4,808 shares of Series D Convertible Preferred Stock as compensation for board services under a Board of Directors Agreement dated February 3, 2025.
Each Series D share is convertible into 100 shares of common stock, so this grant is currently linked to 480,800 common shares, subject to a 4.9% beneficial ownership limitation. The preferred shares generally cannot be converted for six months after issuance, except that conversion occurs immediately in a liquidation. Each preferred share carries 100 votes on stockholder matters, and the right to convert does not expire. Following this grant, Frissora directly holds 71,554 shares of Series D Convertible Preferred Stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Other | Series D Convertible Preferred Stock | 4,808 | $0.00 | -- |
Footnotes (1)
- Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person. The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire.